SNP/genotypea | Regular exercise | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Yes | No | |||||||||||
Case | Control | OR | (95% CI)b | Case | Control | OR | (95% CI)b | |||||
N | (%) | N | (%) | N | (%) | N | (%) | |||||
rs4444235 at 14q22.2 (intergenic) | ||||||||||||
TT | 65 | (28.4) | 185 | (22.2) | 1.00 | (ref.) | 98 | (20.7) | 142 | (25.1) | 1.00 | (ref.) |
TC | 113 | (49.3) | 411 | (49.3) | 0.82 | (0.57–1.17) | 227 | (47.9) | 272 | (48.1) | 1.28 | (0.92–1.78) |
CC | 51 | (22.3) | 237 | (28.5) | 0.58 | (0.38–0.88) | 149 | (31.4) | 151 | (26.7) | 1.47 | (1.02–2.10) |
Additive model | 0.76 | (0.62–0.94) | 1.21 | (1.01–1.44) | ||||||||
Dominant model | 0.72 | (0.52–1.02) | 1.35 | (0.99–1.83) | ||||||||
Recessive model | 0.66 | (0.46–0.94) | 1.24 | (0.94–1.64) | ||||||||
Interaction between rs4444235 and regular exercise | ||||||||||||
Case-onlyc | P for interaction = 2.4 × 10−3 | |||||||||||
Case-controld | P for interaction = 1.5 × 10− 3 | |||||||||||
rs2423279 at 20p12.3 (intergenic) | ||||||||||||
CC | 5 | (25.0) | 75 | (56.0) | 1.00 | (ref.) | 337 | (49.8) | 679 | (53.5) | 1.00 | (ref.) |
CT | 10 | (50.0) | 53 | (39.6) | 4.77 | (1.28–17.73) | 278 | (41.1) | 498 | (39.2) | 1.07 | (0.87–1.33) |
TT | 5 | (25.0) | 6 | (4.5) | 21.19 | (3.82–117.52) | 62 | (9.2) | 93 | (7.3) | 1.27 | (0.87–1.85) |
Additive model | 4.62 | (1.97–10.80) | 1.10 | (0.94–1.29) | ||||||||
Dominant model | 6.30 | (1.80–22.09) | 1.11 | (0.90–1.35) | ||||||||
Recessive model | 8.01 | (2.02–31.78) | 1.23 | (0.86–1.77) | ||||||||
Interaction between rs2423279 and regular aspirin use | ||||||||||||
Case-onlyc | P for interaction = 7.7 × 10−3 | |||||||||||
Case-controld | P for interaction = 1.6 × 10− 3 |